VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwCLL 2019 | Real-world evidence of venetoclax vs ibrutinib vs idelalisib

Toby Eyre, MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, highlights the first real-world evidence of venetoclax vs ibrutinib vs idelalisib in chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter